Outrun Therapeutics

About Outrun Therapeutics

Outrun Therapeutics is a preclinical biotech company focused on unlocking the therapeutic potential of protein stabilisation through E3 ligase inhibition to treat cancer and other diseases, with a mission to empower the body to cure disease.

Products & Services

Proprietary Platform:A platform that has generated a lead programme, a small molecule inhibitor targeting an E3 ligase that destabilises a tumour suppressor protein in hard-to-treat solid tumours.

Specialties

E3 ligase inhibition Protein stabilisation Cancer treatment Small molecule inhibitors

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 10000000 MR: - FA: 10m FAN: 10000000	D: 2024-04-18 FD: 2024-04-18	2 investors

Seed Latest

2024-04-18

$10.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Satpal Virdee

Founder & Non-executive Director

C

Carolyn Porter

CEO

M

Matthew Fyfe

CSO

K

Kerry Jenkins

Senior Director of Chemistry

M

Mathew Stanley

Principal Scientist & Founder

K

Kuan-Chuan Pao

Senior Scientist & Founder

View 11 more team members with Pro

Unlock Full Team Directory

Recent News